Value-Based Contracts: Relief From Regulatory Barriers In Sight?
Executive Summary
Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.
You may also be interested in...
Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges
Amgen has negotiated 75 value-based contracts – agreements that SVP Josh Ofman sees as one area where biopharma and payer views are aligned. However, tension between the two sides remains high in pricing and reimbursement negotiations when it comes to rebates and other issues.
Best Of BIO: Policy & Regulatory Updates From BIO 2017
Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.
BIO Notebook, Day 1: Janssen, Boehringer And More Talk Deals, Pipeline Progress And Investment
Scrip begins its week at the BIO International Convention with interviews and panel discussions about dealmaking and progressing development pipelines. Among the first day highlights: Janssen's hunt for technology, Boehringer's NASH plans and rising investment in neuroscience.